Northwest Biotherapeutics Inc
OTC:NWBO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2
0.32
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Northwest Biotherapeutics Inc
Free Cash Flow
Northwest Biotherapeutics Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Northwest Biotherapeutics Inc
OTC:NWBO
|
Free Cash Flow
-$45.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$19.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.3B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
20%
|
CAGR 10-Years
20%
|
|
Northwest Biotherapeutics Inc
Glance View
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 20 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. Its wholly owned subsidiaries include Flaskworks, Aracaris Ltd, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
See Also
What is Northwest Biotherapeutics Inc's Free Cash Flow?
Free Cash Flow
-45.2m
USD
Based on the financial report for Jun 30, 2025, Northwest Biotherapeutics Inc's Free Cash Flow amounts to -45.2m USD.
What is Northwest Biotherapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
8%
Over the last year, the Free Cash Flow growth was 26%. The average annual Free Cash Flow growth rates for Northwest Biotherapeutics Inc have been 4% over the past three years , -10% over the past five years , and 8% over the past ten years .